Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CNS Pharmaceuticals, Inc. - Common Stock (NQ:CNSP)

6.030 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CNS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Webull Financial Biotech/MedTech Webinar Series
Via Investor Brand Network
What Women Need to Know About Benign Brain Tumors
Via Investor Brand Network
CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
Via ACCESS Newswire
Study Reveals Potential Way to Treat Pediatric Gliomas
Via Investor Brand Network
Study Identifies Genetic Marker Helpful in Guiding Brain Tumor Treatment
Via Investor Brand Network
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Virtual Investor Summer Spotlight Conference
Via Investor Brand Network
Unexpected Finding Potentially Opens the Door to Universal Vaccines Against Cancer
Via Investor Brand Network
CNS Pharmaceuticals to Participate in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference
Via ACCESS Newswire
JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live
Via ACCESS Newswire
New Machine Learning Model Predicts Cancer Severity, Aids Treatment Planning
Via Investor Brand Network
TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 1-for-12 Reverse Stock Split Effective July 22
Via Investor Brand Network
CNS Pharmaceuticals Announces Reverse Stock Split
Via ACCESS Newswire
New Study Suggests Concussions Could Lead to Higher Risks of Brain Cancer
Via Investor Brand Network
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Lead Program in Virtual CEO Segment
Via Investor Brand Network
CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment
Via ACCESS Newswire
Discover the top movers in Thursday's pre-market session.
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Research Links Key Proteins to the Growth of Brain Tumors
Via Investor Brand Network
New Scanning Method Could Improve How Brain Tumors are Treated
Via Investor Brand Network
TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights GBM Treatment Insights in KOL Segment Featuring Dr. Erin Dunbar
Via Investor Brand Network
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287
Via ACCESS Newswire
New Study Shows TTFields Amplify Immune Attack Against Brain Cancer
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present Promising Glioblastoma Data at Brain Tumor Biotech Summit
Via Investor Brand Network
CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit
Via ACCESS Newswire
Hundreds Sue Pfizer Over Birth Control Jabs Linked to Brain Tumors
Via Investor Brand Network
Topics Lawsuit
Study Finds That Kids, Young People Wait Longer to Receive a Cancer Diagnosis
Via Investor Brand Network
Experts Say New Test for Brain Tumors is a Game-Changer
Via Investor Brand Network
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q1 Loss, Highlights Progress on TPI 287 for Brain Cancer
Via Investor Brand Network
CNS Pharmaceuticals Stock Declines On Wider Q1 Loss: But Retail Stays Unmoved
The company intends to commence the phase 2 study of its lead program, TPI 287, to treat Glioblastoma Multiforme (GBM) by year-end. 
Via Stocktwits
CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.